Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 5/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807294 | 0.83 | MAPT (0.46) | NAMPTIRAK4SLC6A7ALDH1A1GAA | |
| SCHEMBL4813430 | 0.79 | NAMPT (0.49) | NAMPTSLC6A7KDM4EDRD4 | |
| SCHEMBL4815951 | 0.77 | SLC6A7 (0.41) | EPHX2IRAK4SLC6A7MAPK1ALDH1A1 | |
| SCHEMBL4812861 | 0.75 | IRAK4 (0.40) | EPHX2IRAK4SLC6A7MAPK1ALDH1A1 | |
| SCHEMBL4819635 | 0.74 | ADRA1D (0.42) | EPHX2NAMPTIRAK4SLC6A7MAPK1 | |
| SCHEMBL2178464 | 0.74 | HTT (0.46) | ALDH1A1MAPTLMNAHSD17B10KDM4E | |
| SCHEMBL2179068 | 0.73 | NAMPT (0.44) | NAMPTSLC6A7MAPTDRD4 | |
| SCHEMBL2228921 | 0.71 | MAPT (0.51) | MAPK1ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL3325476 | 0.71 | MAPT (0.50) | JAK1ALDH1A1GAAMAPT | |
| SCHEMBL15203469 | 0.71 | CHRM1 (0.42) | ALDH1A1MAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468368-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2008-12-23 | — | — | US | claimed |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | claimed |
| US-7468368-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| EP-1513835-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-08-16 | — | — | EP | disclosed |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C1, CBR1 | JAK1 3811/4885JAK2 2569/4885EPHX2 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.